Clinical Trial Update: Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing vorinostat (MK-0683) to placebo in advanced malignant pleural mesothelioma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Mesothelioma, Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-10-26